• slidebg1
  • slidebg1
  • slidebg1
  • slidebg1
  • slidebg1
  • 23
    06/17
    NEWS
    Chiesi Farmaceutici completes the acquisition of European Marketing Rights
    Chiesi Farmaceutici completes the acquisition of European Marketing Rights to PROCYSBI® (cysteamine bitartrate)...
  • PRESS RELEASE
    TRIBUTE study shows superiority of Chiesi’s Trimbow® (Beclometasone...
    Chiesi completed a long-term clinical study with its extrafine fixed-dose triple combination inhaler (Trimbow®) in a single...